GSK, Merck agree on HPV vax discount with GAVI – FierceVaccines

GSK, Merck agree on HPV vax discount with GAVI
FierceVaccines
Social issues have held back uptake of GlaxoSmithKline's ($GSK) and Merck's ($MRK) human papillomavirus (HPV) vaccines in the U.S., but globally the problem is more fundamental–the shots cost too much. But it is these low-income countries–where 85%

View full post on hpv – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *